Show results for
Refine by
Epitope Suppliers Serving Spain
70 companies found
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like ...
based inMartinsried, GERMANY
Proteros is a Munich-based provider of structure-based early stage drug discovery services with a cutting-edge discovery engine tailored to unlock even the most technically challenging drug targets. Proteros supports its clients to reach the right ...
based inShirley, NEW YORK (USA)
CD BioSciences is a leading customer-focused biotechnology company founded in New York. Virus-like particles (VLPs) constructed on plant-based platforms can be produced on a large scale as plants can be grown cheaply and efficiently without the need ...
As is a leading global custom service provider, CD BioSciences dedicated to delivering highly customized and integrated solutions with the best quality to advance our customers' projects. CD BioSciences has a sophisticated VLPlantTM platform and ...
based inCambridge, UNITED KINGDOM
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and ...
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a ...
based inPhoenix, ARIZONA (USA)
Ordinatrix builds on over a decade of development and refinement of the Nucleic Acid Programmable Protein Arrays (NAPPA) technology. Ordinatrix provides a customizable solution for analysis of the proteome with the commercial introduction of the ...
Protein microarrays display proteins in high spatial density on a microscopic surface. They can be used to test a variety of functions of many proteins simultaneously including interactions with other macromolecules, functional activity, and their ...
based inHørsholm, DENMARK
We are an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. We have developed our AI-immunology core technology to deeply understand the biological ...
RAVEN is our third proprietary AI platform that brings our unique, machine learning approach to vaccine design and development for viral diseases. RAVEN combines the essential AI tools from our PIONEER platform with structural bioinformatic tools ...
based inNew Delhi, INDIA
Takara Bio companies provide kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, DSS Takara Bio India Private Ltd. is part of a company that holds ...
SARS-CoV-2 research is happening at breakneck speed, and scientists are trying to identify epitopes that could trigger an immune response to the virus, an important step in the development of novel vaccines. Takara Bio offers an ...
based inVannas, SWEDEN
Agrisera is a Swedish company, established in 1985, specialized in antibody production and purification. Since 2020, Agrisera is a part of Olink Group. Agrisera provides off-the-shelf antibodies for plant and algal research, with prompt delivery ...
The Rubisco quantitation kit is suitable for quantitation of Rubisco in plant and algal samplesusing quantitative immunoblotting. It contains anti-RbcL antibody, Rubisco protein standard and theProtein Extraction Buffer for quantitative protein ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
Label-free interaction analysis is of great importance for scientists to study interactions between biomolecules. Scientists from Creative Biolabs are competent for performing antibody affinity and kinetics measurement with the most advanced ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in ...
based inLake Forest Park, WASHINGTON (USA)
IEH was founded in 2001 by Dalia Alfi and Mansour Samadpour, who left their positions at the University of Washington, School of Public Health, to start the company. It is a family-owned and operated company and has grown rapidly since 2001, both ...
Undeclared allergens constitute a large portion of food recalls, and there is a tendency to underestimate the impact of allergens on susceptible populations. We offer a comprehensive array of qualitative and quantitative allergen testing, food ...
based inPeachtree Corners, GEORGIA (US) (USA)
RayBiotech is a leading life sciences company providing proteomic discovery tools. RayBiotech has nearly 150 employees whose objectives are to provide excellent products and service worldwide to RayBiotech customers which include scientists in ...
The SARS-CoV-2 Spike Protein Overlapping Peptide Array is semi-quantitative array displaying 316 synthesized peptides representing the full-length SARS-CoV-2 Spike protein (wild-type). It is suitable for antibody epitope mapping and ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also plays an ...
based in, NEW JERSEY (USA)
Founded in 2013 by a group of passionate synthetic biologists with decades of industry experience and a proven track record of delivering cost-effective DNA solutions, Synbio Technologies is incorporated with a single mission in mind: to empower ...
Hybridoma technology features the effective usage of innate functions of both immune and cancer cells to generate monoclonal antibodies (mAbs). The resulting hybridoma cell lines are produced to combat specific antigens of interest. Such technology ...
based inHercules, CALIFORNIA (USA)
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products ...
Mouse anti Human von Willebrand factor antibody, clone RFF-VIII R/1 recognizes human von Willebrand factor (vWF), also known as Factor VIII related antigen, a blood glycoprotein involved in blood coagulation. It stabilises circulating Factor VIII by ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The Celluris’ novel solution, named RfuCAR, was engineering in order to respond some challenges addressed by clinical trials around the world. RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and ...
based inNew York, NEW YORK (USA)
Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We are dedicated to offering custom peptide synthesis, process development, GMP manufacturing as well as catalog products for customers in ...
On the basis of extensive experience in peptide synthesis, Creative Peptides proudly offers the most comprehensive glycopeptides synthesis services to our worldwide clients. Our scientists are committed to deliver high quality glycopeptides which ...
based inThurleigh (Bedfordshire), UNITED KINGDOM
Global Access Diagnostics (GADx) is a leading developer of lateral flow and rapid diagnostic technologies, products and services, offering a full suite of services from concept to validation to manufacturing at flexible volumes. Bringing skills ...
GADx has produced hundreds of rare biomolecules for clients and for our own in-house development. Our expertise is in the production of highly specific and well characterized reagents including those used in immunoassays where performance is ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...